MedTrace Logo

Pletaal SR Post Marketing Observational Study

NCT01782833 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3635

Last updated 2019-03-01

Study results available
· View outcomes & findings →

Summary

This is a Post Marketing Observational Study of cilostazol (Pletaal® SR capsule). As this study is observational in nature to collect the safety data after administrating the Pletaal SR capsule, from baseline to 16 weeks.

Conditions

  • Ischemic Symptoms
  • Cerebral Infarction

Interventions

OTHER

This is Non-interventional study

Sponsors & Collaborators

  • Korea Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01782833 on ClinicalTrials.gov